1. Home
  2. Analytics
  3. Basic

Curaizon Basic Review

About Project

Name: CURATOKEN

Ticker symbol: CTKN

Project type: Healthcare technology

Company description (detailed): Curaizon™ is an ecosystem in which doctors can monitor patients’ conditions, researchers can collect data for their studies and patients can make sure they take their medicines as prescribed.

Company: Curaizon™ ltd.

Website

Whitepaper

 

ICO details

Public ICO start date: June 8, 2018

Public ICO end date: July 9, 2018

Token sale duration (weeks): 4

Token type: EIP-20 Ethereum based

Total token supply: 500,000,000

Tokens to be sold (Pre-Sale + Public ICO): 250,000,000

Fundraising purposes:

Price: 1 CTKN = 0.20 USD

Accepted currencies: ETH

Bounty program: up to 5,000,000 CTKN

Token function: Utility (access token)

 

Team

Number of team members: 20+

Number of advisors and partners:  3

GitHub: n/a

 

Project

Curaizon™ is an ecosystem where doctors can monitor patients’ conditions in real-time, researchers can collect data for their studies and patients can make sure they take their medicines as prescribed. The ecosystem integrates the following solutions: a) CuraServe, that reminds patients to take medicines; b) CuraView, providing patient data for doctors; c) CuraData, that collects patient data.

The platform offers the following functionality:

1) patient reminders to take medicines.

2) patients can benchmark against peer groups.

3) family and doctors can monitor a patient’s condition in real time.

4) researchers and scientists will be able to access data using tokens.

 

Project advisors:

  • Rory McCrea (LinkedIn) – Chairman of the Board at  ChilversMcCrea Consultancy, Amie Healthcare.

  • Sarah Chilvers (LinkedIn) – Project Manager at MSD Sharp & Dohme GmbH and CEO at ChilversMcCrea Healthcare Ltd. Formerly Project Manager at Novartis.

  • Parexel (LinkedIn) – a biometrics service company.

Project partners: n/a

Attracted funds: n/a

 

Summary

The basis of this project is a platform enabling doctors and patients to exchange information, patients to receive reminders to take medicines and researchers and scientists to purchase patient data.  

Project strengths:

  • according to the roadmap, the platform is almost ready for release.

  • the project has experienced advisors.

  • the market is developing at a fast pace.

Project shortcomings:

  • there are not enough strategic partners for future business, given that the company intends to sell software through clinics.

  • the project is not yet well-known in the blockchain community.

Market and Industry

According to the project documentation, the platform’s main source of income will be chargeable provision of data for researchers.  As per information from Newswire, the healthcare data market is expected to become almost five times larger and reach $68.75 billion by 2025.

The team have provided the following information:

  • only about 50% of people in developed countries take their medications as prescribed.

  • drug non-adherence accounts for over 50% of visits to a doctor and more than 50% of hospital readmissions.

  • worldwide drug non-adherence results in approximately $700 billion in additional healthcare costs.

  • healthcare costs for non-adherent patients can be as much as $2,000 per patient a year in additional doctor visits alone.

The potential number of users the platform hopes to attract is 1.4 billion.

Comment: The market is growing at a fast pace, making it possible for the project to occupy a niche.

Competitors

  • Patientory is a platform that enables family members and doctors to monitor a patient’s condition.

  • Citiustech is a platform that facilitates healthcare data collection and storage.

  • Liaison is a platform designed for the collection and analysis of data to be later sold to scientists and researchers.

Conclusion: The main platform advantage is that it envisages both an electronic health record for monitoring a patients’s state during long-term and chronic illness, and provision of healthcare data. This data would be used for research and forecasting regarding a patient's condition.

Platform Technical Parameters

The platform is based on blockchain technology and employs smart contracts.

All data are stored off-chain in an encrypted AES 256 cloud, in an appropriate geographic domain with the blockchain storing pointers, access and usage rules.

The platform also employs machine learning technologies to determine the best treatment approach and model patient behavior.

 

Technical description

The Curaizon ecosystem includes CuraServe, CuraData and CuraView.

1) СuraServe: This system communicates with patients and reminds them to take medicines. All patients are interconnected and in the event that a participant does not take their prescribed medication, the system will not interact with their emergency contact. Such a solution stimulates the patients to take their medications on time.

2) CuraView: This system is integrated with legacy healthcare systems. It ensures that all patient data is constantly updated and interacts with electronic health records, enabling doctors and commissioners to determine any weaknesses within the system.

3) CuraData: This system collects data about patients and their conditions and transfers it to CuraView. The data can be used by researchers to determine the impact of certain medicines and deliver optimizations.  

All family members and doctors can access data about a patient’s condition, their treatment plan and forecasts.

Comment: The project employs current technologies that have proven effective.

 

Technical roadmap

The team are planning to further develop the technologies, collect the required data and subsequently implement the following:

  • August 2018: CuraData beta launch.

  • November 2018: CuraData official release.

  • December 2018: Curaizon completes clinical trials and launches CuraServe.

  • 2020: CuraData 2.0 release.  

 

Comment: The team have finished API development; they have also implemented CuraServe and CuraView. The smart contract has not yet been made available.

Documentation

We have analyzed the Curatoken site and documentation to determine whether they provide sufficient and consistent information for an investment decision to be made.

Project information can be found in the White Paper and the Light Paper; these documents are available in English. The White Paper provides a detailed description of the project. Specific attention is paid to platform functionality.

The website also provides information on the project, team, advisors and roadmap. It has a FAQ section. The site is available in English.

Conclusion: The documentation provides sufficient information for gaining an idea about the project. The platform’s functionality is described in extensive detail.

ICO

Tokens to be sold: 50%

Public ICO start date: June 8, 2018

Token type: EIP-20 Ethereum-based

Accepted currencies: ETH

Price: 1 CTKN = 0.20 USD

Crowd sale duration: 4 weeks (ends on July 9, 2018)

CuraTokenTM («CTKN») is a EIR-20 Ethereum-based token that can be used to access healthcare data through Curaizon’s platform, CuraData.

Token issuance limit: 500,000,000

Advantages for token holders: Being utility tokens, the tokens can be used to access the platform services or may be sold.

Dividends: none

Additional token emission: none

Escrow: n/a

The tokens will be sold in several stages with the following bonuses:

Hard cap: 25,000,000 USD

Bounty

Conclusion: As the team has stated in Telegram, their bonus program is designed for large financial contributors.

Token and Funds Allocation

Tokens and funds will be allocated as follows:

Conclusion: Tokens do not affect the company share allotment. The incentive system encourages early token purchase.

Roadmap

Project  Roadmap:

  • January 2019: EU markets entry.

Conclusion: The team are planning to sell the solution to healthcare institutions and attract users to the platform via this method.

Team

The project team features 5 members and 3 advisors. LinkedIn profiles for key members provide the following information:

  • Nicholas James Rumble (LinkedIn) - Chief Executive Officer (CEO). He holds the CEO position at Simian Capital Ltd. Nicholas was the Head of Business Development for the Asia Pacific region at Saxo Bank Group.

  • Chris Matey (LinkedIn) - Chief Financial Officer (CFO). Chris is the CEO of the Blue Note Consulting Group. He was formerly president and co-founder of Red Apple Renovations and a Product Marketing Manager at MetraTech Corp.

  • Darran Trute (LinkedIn) - Chief Technology Officer (CTO). He is a Community Lead at block3 and a Transformation Manager at Tea-m. Darran is co-owner of Positive News.

There are another two members on the team.

Conclusion: All team members confirmed their involvement in the project. The team are mainly from the UK, and include an ICO Director and Chief Data Officer.

Marketing

Information on the project is available via major services such as Twitter, Telegram, Medium, Facebook, Bitcointalk and Youtube. The project has an active bounty program.  

The team are running a social network marketing campaign. Their Twitter and Facebook newsfeeds are regularly updated.

The majority of articles have been commissioned by the team to raise awareness about the upcoming ICO among potential investors.

Comment: The marketing campaign is mainly being developed via Bitcointalk and Twitter.

Below are the results of a traffic analysis of the Curatoken site based on data from BE1.ru:

Traffic source

Comment: 100% direct traffic

100% of traffic comes from Pakistan.

Conclusion: Based on available data, we conclude that a sufficient number of users are not yet interested in the project. The team are running a marketing campaign via Twitter, Bitcointalk and Facebook, communicating with users via Telegram and posting YouTube videos about the project. In April the website was visited by approximately 52 people. 

Contacts

You can contact the developers via the following links:

Website

Twitter

Telegram

Medium

Facebook

Bitcointalk

Youtube

The information contained in the document is for informational purposes only. ICORating received monetary compensation from the entity rated in this report for completing the ratings report. However, the entity rated in this report did not have the opportunity to approve this rating report before the report was published, nor did the rated entity have the opportunity to edit or remove this report once it was published. The views expressed in this document are solely those of the ICORating Team, based on data obtained from open access and information that developers provided to the team through Skype, email or other means of communication. Our goal is to increase the transparency and reliability of the young ICO market and to minimize the risk of fraud. We appreciate feedback with constructive comments, suggestions and ideas on how to make the analysis more comprehensive and informative.